- Home
- LSB vs IGC Comparison
LSB vs IGC Comparison
Compare LSB & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- IGC
- Stock Information
- Founded
- LSB 2002
- IGC 2005
- Country
- LSB China
- IGC United States
- Employees
- LSB N/A
- IGC N/A
- Industry
- LSB
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- LSB
- IGC Health Care
- Exchange
- LSB NYSE
- IGC Nasdaq
- Market Cap
- LSB 20.4M
- IGC 33.5M
- IPO Year
- LSB N/A
- IGC N/A
- Fundamental
- Price
- LSB $0.87
- IGC $0.36
- Analyst Decision
- LSB
- IGC Strong Buy
- Analyst Count
- LSB 0
- IGC 2
- Target Price
- LSB N/A
- IGC $3.88
- AVG Volume (30 Days)
- LSB 872.0K
- IGC 7.6M
- Earning Date
- LSB 08-05-2025
- IGC 08-07-2025
- Dividend Yield
- LSB N/A
- IGC N/A
- EPS Growth
- LSB N/A
- IGC N/A
- EPS
- LSB N/A
- IGC N/A
- Revenue
- LSB $79,415,311.00
- IGC $1,271,000.00
- Revenue This Year
- LSB $39.33
- IGC $15.26
- Revenue Next Year
- LSB $75.61
- IGC $3.41
- P/E Ratio
- LSB N/A
- IGC N/A
- Revenue Growth
- LSB N/A
- IGC N/A
- 52 Week Low
- LSB $0.36
- IGC $0.25
- 52 Week High
- LSB $6.82
- IGC $0.48
- Technical
- Relative Strength Index (RSI)
- LSB 40.85
- IGC 54.87
- Support Level
- LSB $1.02
- IGC $0.35
- Resistance Level
- LSB $1.35
- IGC $0.39
- Average True Range (ATR)
- LSB 0.14
- IGC 0.04
- MACD
- LSB -0.02
- IGC 0.00
- Stochastic Oscillator
- LSB 0.00
- IGC 35.71
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.